Previous 10 | Next 10 |
home / stock / bayzf / bayzf news
Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...
Inflation concerns have started to affect market sentiment, but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market ...
Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are ...
ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay...
Investing in Bayer isn't for the faint-hearted given the company's recent and likely future valuation and earnings volatility. However, beneath the hood there's a qualitative company with superb fundamentals and an excellent portfolio. At a certain valuation, this cannot be anythi...
Bayer Aktiengesellschaft (BAYZF) Q3 2021 Earnings Conference Call Nov 09, 2021 08:00 AM ET Company Participants Oliver Maier - Head, Investor Relations Werner Baumann - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Stefan Oelrich - President, Pharmaceuticals Division Liam C...
The following slide deck was published by Bayer Aktiengesellschaft in conjunction with their 2021 Q3 earnings call. For further details see: Bayer Aktiengesellschaft 2021 Q3 - Results - Earnings Call Presentation
Bayer (OTCPK:BAYRY +1.2%) moves higher after Q3 EBITDA jumped 16% Y/Y to €2.09B (~$2.4B), topping an average analyst forecast of €1.94B, and revenues rose 15% to €9.78B. Bayer swung to a Q3 net profit of €85M from a €2.74B net loss a year earlier, when resul...
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...
Evotec SE (EVO) has downsized its proposed U.S. IPO to 20M American Depository Shares from previously proposed 22M. As a result, the German biotech now expects gross proceeds of $435M based on a price of $21.75 per ADS. Evotec's latest stage candidate is EVT201 in phase 3 for insomnia with pa...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG Registered Shares Company Name:
BAYZF Stock Symbol:
OTCMKTS Market:
NORTHAMPTON, MA / ACCESSWIRE / August 29, 2023 / Bayer - As climate change quickens, societal expectations increase and the threat of resistance grows, new crop protection solutions are imperative. Advances in the life sciences and data-driven technologies hold the key to expanding our pipeline ...
Monsanto Must Face Georgia State Jurors in Lawsuit Over Cancer-Causing Roundup Herbicide PR Newswire 11th Circuit opinion finds chemical giant subject to state's warning label laws Nachawati Law Group trial lawyers gearing up for next Roundup cancer trial in Au...
Bayer Runs Out of Appeals at US Supreme Court as Thousands of Cancer Lawsuits Await over Roundup Herbicide PR Newswire Fears Nachawati trial lawyers gearing up for next Roundup cancer trial in August WASHINGTON , June 22, 2022 /PRNewswire/ -- Baye...